Fennec Pharmaceuticals Inc. (FRX.TO)
CAD 8.12
(-6.34%)
CAD 8.12
(-6.34%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -16.04 Million USD | 32.76% |
| 2022 | -23.86 Million USD | -36.69% |
| 2021 | -17.45 Million USD | 2.6% |
| 2020 | -17.92 Million USD | -43.84% |
| 2019 | -12.46 Million USD | -26.01% |
| 2018 | -9.88 Million USD | -40.33% |
| 2017 | -7.04 Million USD | -152.64% |
| 2016 | -2.78 Million USD | -323.22% |
| 2015 | -659 Thousand USD | 69.72% |
| 2014 | -2.17 Million USD | -217.94% |
| 2013 | 1.84 Million USD | 135.74% |
| 2012 | -5.16 Million USD | -210.2% |
| 2011 | 4.68 Million USD | 159.89% |
| 2010 | -7.82 Million USD | -159.73% |
| 2009 | -3.01 Million USD | 77.85% |
| 2008 | -13.6 Million USD | -1.82% |
| 2007 | -13.35 Million USD | 30.08% |
| 2006 | -19.1 Million USD | 0.74% |
| 2005 | -19.24 Million USD | 0.0% |
| 2003 | -8.73 Million USD | -42.13% |
| 2002 | -6.14 Million USD | -65.26% |
| 2001 | -3.71 Million USD | -51.53% |
| 2000 | -2.45 Million USD | -53.67% |
| 1999 | -1.59 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -5.55 Million USD | -143.26% |
| 2024 Q1 | 12.83 Million USD | 578.64% |
| 2023 Q3 | -1.86 Million USD | 65.71% |
| 2023 Q1 | -6.07 Million USD | 11.15% |
| 2023 Q2 | -5.44 Million USD | 10.36% |
| 2023 Q4 | -2.68 Million USD | -43.65% |
| 2023 FY | -16.04 Million USD | 32.76% |
| 2022 Q4 | -6.83 Million USD | 16.24% |
| 2022 Q1 | -3.78 Million USD | 14.43% |
| 2022 FY | -23.86 Million USD | -36.69% |
| 2022 Q3 | -8.16 Million USD | -60.69% |
| 2022 Q2 | -5.07 Million USD | -34.05% |
| 2021 Q2 | -4 Million USD | 15.47% |
| 2021 Q3 | -4.18 Million USD | -4.6% |
| 2021 Q4 | -4.42 Million USD | -5.78% |
| 2021 FY | -17.45 Million USD | 2.6% |
| 2021 Q1 | -4.73 Million USD | -46.17% |
| 2020 Q3 | -6.2 Million USD | -27.97% |
| 2020 Q1 | -3.82 Million USD | -5.98% |
| 2020 Q4 | -3.23 Million USD | 47.77% |
| 2020 FY | -17.92 Million USD | -43.84% |
| 2020 Q2 | -4.84 Million USD | -26.63% |
| 2019 Q1 | -2.62 Million USD | 12.0% |
| 2019 Q3 | -1.8 Million USD | 61.75% |
| 2019 Q2 | -4.73 Million USD | -80.12% |
| 2019 FY | -12.46 Million USD | -26.01% |
| 2019 Q4 | -3.61 Million USD | -99.56% |
| 2018 Q2 | -2.58 Million USD | -64.99% |
| 2018 Q3 | -2.74 Million USD | -6.26% |
| 2018 Q4 | -2.98 Million USD | -8.55% |
| 2018 Q1 | -1.56 Million USD | 31.53% |
| 2018 FY | -9.88 Million USD | -40.33% |
| 2017 FY | -7.04 Million USD | -152.64% |
| 2017 Q2 | -1.59 Million USD | -98.26% |
| 2017 Q4 | -2.29 Million USD | 2.64% |
| 2017 Q3 | -2.35 Million USD | -47.18% |
| 2017 Q1 | -806 Thousand USD | 29.48% |
| 2016 Q4 | -1.14 Million USD | -127.69% |
| 2016 FY | -2.78 Million USD | -323.22% |
| 2016 Q1 | -420 Thousand USD | 22.22% |
| 2016 Q3 | -502 Thousand USD | 30.66% |
| 2016 Q2 | -724 Thousand USD | -72.38% |
| 2015 Q1 | 177 Thousand USD | -87.25% |
| 2015 Q3 | -123 Thousand USD | 28.9% |
| 2015 Q4 | -540 Thousand USD | -339.02% |
| 2015 Q2 | -173 Thousand USD | -197.74% |
| 2015 FY | -659 Thousand USD | 69.72% |
| 2014 Q1 | -3.19 Million USD | -387.49% |
| 2014 Q4 | 1.38 Million USD | 265.26% |
| 2014 Q2 | -750 Thousand USD | 76.52% |
| 2014 Q3 | 380 Thousand USD | 150.67% |
| 2014 FY | -2.17 Million USD | -217.94% |
| 2013 Q3 | -1.76 Million USD | -126.73% |
| 2013 Q4 | 1.11 Million USD | 162.91% |
| 2013 FY | 1.84 Million USD | 135.74% |
| 2013 Q2 | 6.6 Million USD | 260.83% |
| 2013 Q1 | -4.1 Million USD | 36.91% |
| 2012 Q1 | 2.71 Million USD | -22.63% |
| 2012 Q3 | -764 Thousand USD | -26.91% |
| 2012 Q4 | -6.51 Million USD | -752.23% |
| 2012 FY | -5.16 Million USD | -210.2% |
| 2012 Q2 | -602 Thousand USD | -122.17% |
| 2011 FY | 4.68 Million USD | 159.89% |
| 2011 Q4 | 3.5 Million USD | 211.61% |
| 2011 Q3 | -3.14 Million USD | -803.45% |
| 2011 Q2 | -348 Thousand USD | -107.45% |
| 2011 Q1 | 4.66 Million USD | 170.93% |
| 2010 Q1 | -366 Thousand USD | -276.81% |
| 2010 FY | -7.82 Million USD | -159.73% |
| 2010 Q4 | -6.58 Million USD | -488.61% |
| 2010 Q3 | 1.69 Million USD | 391324.02% |
| 2010 Q2 | -433.00 USD | 99.88% |
| 2009 FY | -3.01 Million USD | 77.85% |
| 2009 Q4 | 207 Thousand USD | 691.43% |
| 2009 Q3 | -35 Thousand USD | 96.27% |
| 2009 Q2 | -938 Thousand USD | 58.24% |
| 2009 Q1 | -2.24 Million USD | 13.95% |
| 2008 Q2 | -3.44 Million USD | 20.03% |
| 2008 Q1 | -4.3 Million USD | -43.09% |
| 2008 FY | -13.6 Million USD | -1.82% |
| 2008 Q4 | -2.61 Million USD | 19.54% |
| 2008 Q3 | -3.24 Million USD | 5.75% |
| 2007 FY | -13.35 Million USD | 30.08% |
| 2007 Q4 | -3 Million USD | 6.06% |
| 2007 Q1 | -3.96 Million USD | 37.89% |
| 2007 Q2 | -3.17 Million USD | 19.88% |
| 2007 Q3 | -3.2 Million USD | -0.72% |
| 2006 Q4 | -6.38 Million USD | -27.96% |
| 2006 FY | -19.1 Million USD | 0.74% |
| 2006 Q3 | -4.99 Million USD | -18.91% |
| 2006 Q2 | -4.19 Million USD | -19.22% |
| 2006 Q1 | -3.52 Million USD | 50.4% |
| 2005 Q3 | -4.4 Million USD | 4.73% |
| 2005 Q2 | -4.62 Million USD | -48.2% |
| 2005 Q1 | -3.11 Million USD | 0.0% |
| 2005 Q4 | -7.1 Million USD | -61.24% |
| 2005 FY | -19.24 Million USD | 0.0% |
| 2004 Q1 | -2.4 Million USD | -13.78% |
| 2004 Q3 | -2.85 Million USD | -8.52% |
| 2004 Q2 | -2.63 Million USD | -9.66% |
| 2003 Q2 | -2.09 Million USD | -23.71% |
| 2003 FY | -8.73 Million USD | -42.13% |
| 2003 Q4 | -2.11 Million USD | -33.71% |
| 2003 Q3 | -1.57 Million USD | 24.74% |
| 2003 Q1 | -1.69 Million USD | -58.27% |
| 2002 Q3 | -1.11 Million USD | 22.73% |
| 2002 Q2 | -1.44 Million USD | -63.41% |
| 2002 Q1 | -883.2 Thousand USD | -64.21% |
| 2002 FY | -6.14 Million USD | -65.26% |
| 2002 Q4 | -1.07 Million USD | 3.91% |
| 2001 Q2 | -687.23 Thousand USD | 10.24% |
| 2001 FY | -3.71 Million USD | -51.53% |
| 2001 Q4 | -537.85 Thousand USD | 37.75% |
| 2001 Q3 | -864.03 Thousand USD | -25.73% |
| 2001 Q1 | -765.65 Thousand USD | -45.42% |
| 2000 FY | -2.45 Million USD | -53.67% |
| 2000 Q3 | -525.41 Thousand USD | 0.0% |
| 2000 Q4 | -526.5 Thousand USD | -0.21% |
| 1999 FY | -1.59 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -3.78 Million CAD | -324.369% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 57.089% |
| Helix BioPharma Corp. | -9.26 Million CAD | -73.197% |
| Microbix Biosystems Inc. | -39.48 Thousand CAD | -40537.743% |
| Medicenna Therapeutics Corp. | -25.46 Million CAD | 36.994% |
| Satellos Bioscience Inc. | -15.88 Million CAD | -0.982% |
| Oncolytics Biotech Inc. | -27.75 Million CAD | 42.184% |
| Sernova Corp. | -38.99 Million CAD | 58.856% |